Drug Profile
Research programme: human monoclonal antibodies - Medarex/Raven
Alternative Names: Human monoclonal antibodies research programme - Medarex/RavenLatest Information Update: 08 Sep 2003
Price :
$50
*
At a glance
- Originator Medarex; Raven biotechnologies
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ovarian cancer
Most Recent Events
- 08 Sep 2003 Discontinued - Preclinical for Ovarian cancer in USA (unspecified route)
- 10 Apr 2000 Preclinical development for Ovarian cancer in USA (Unknown route)